Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears IQuum's Influenza A/B Assay

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has given 510(k) clearance to IQuum's assay for detecting and differentiating influenza A and B in about 20 minutes, the company announced today.

IQuum's Liat Influenza A/B Assay and Liat Analyzer is an automated sample-to-result multiplex real-time RT-PCR assay intended for use in CLIA-certified laboratories. According to IQuum, it is the only test that has sensitivity and specificity equivalent to or better than current lab-based nucleic acid tests, as well as time to result and ease of use comparable to immunoassays.

The assay, which is also CE marked, requires one minute of operator hands-on time and can achieve results in about 20 minutes, making it appropriate for hospital near-patient settings, the Marlborough, Mass.-based firm said.

"IQuum's goal is to provide sophisticated nucleic acid tests that can be performed in near-patient settings and deliver accurate results to physicians and patients instantly," IQuum CEO Shuqi Chen said in a statement.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.